MEDINCELL |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.9 EUR | 0.00% |
|
0.00% | 0.00% |
| 15/05 | Medincell: share price falls after disappointing clinical study | CF |
| 15/05 | Transcript : MedinCell S.A. - Special Call |
Business Summary
As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Sales per Business
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Products Received under Development Benefit
58.6
%
| 4 | 97.5 % | 6 | 58.6 % | +45.37% |
Licenses, Milestones
29.3
%
| - | - | 3 | 29.3 % | - |
Royalties
12.0
%
| 0 | 2.5 % | 1 | 12.0 % | +1,077.23% |
Sales per region
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
France
100.0
%
| 4 | 100.0 % | 10 | 100.0 % | +141.78% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 60 | 09/03/09 |
Stéphane Postic
DFI | Director of Finance/CFO | 50 | 01/23/01 |
| Chief Tech/Sci/R&D Officer | - | 01/15/01 | |
Sébastien Magnat
COO | Chief Operating Officer | - | 01/16/01 |
| Chief Tech/Sci/R&D Officer | - | 01/08/01 | |
Richard Malamut
CTO | Chief Tech/Sci/R&D Officer | 64 | 09/22/09 |
Grace Kim
IRC | Investor Relations Contact | - | 19/23/19 |
| - | - | ||
Julie Alimi
LAW | General Counsel | - | - |
Franck Pouzache
HRO | Human Resources Officer | - | 01/20/01 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sabri Markabi
BRD | Director/Board Member | - | 05/17/05 |
Tone Kvåle
BRD | Director/Board Member | 55 | 13/22/13 |
Virginie Lleu
BRD | Director/Board Member | - | 25/16/25 |
Philippe Guy
CHM | Chairman | - | 16/10/16 |
Elisabeth Kogan
BRD | Director/Board Member | - | 15/20/15 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 28,750,645 | 14,384,856 ( 50.03 %) | 30,646 ( 0.1066 %) | 50.03 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
MEDINCELL S.A. 0.03% | 7,550 | 0.03% | 115,926 $ |
Company contact information
Sector
Sales per Business
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.16
EUR
Average target price
19.24
EUR
Spread / Average Target
+26.91%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +38.59% | 727B | |
| -7.89% | 347B | |
| +15.66% | 319B | |
| +0.24% | 274B | |
| +12.98% | 238B | |
| +6.99% | 204B | |
| -6.46% | 203B | |
| +4.23% | 161B | |
| -1.70% | 160B |
- Stock Market
- Equities
- MEDCL Stock
- Stock
- Company MedinCell
